Iovance Biotherapeutics, Inc. Common Stock (IOVA) Ownership & Trading Activity

Institutional holders, insider transactions, and congressional trades for IOVA. 13F holdings as of 2026-09-30.

In 13F filings for the quarter ended September 30, 2026, 255 institutions reported holding IOVA, with 175.8 million shares worth $2.6 billion in aggregate.

Top Institutional Holders

InstitutionSharesValueChange
BlackRock37,903,960$562MINCREASED
Vanguard33,907,351$503MDECREASED
State Street21,695,003$322MDECREASED
Geode Capital Management10,452,242$155MINCREASED
Dimensional Fund Advisors6,238,693$92MDECREASED

Recent Insider Trades

InsiderTypeSharesValueDate
Frederick G Vogt (Interim CEO & General Counsel)EXERCISE200,000$2M2026-11-11
Frederick G Vogt (Interim CEO & General Counsel)TAX-W191,303$2M2026-11-11
Frederick G Vogt (Interim CEO & General Counsel)EXERCISE200,000$2M2026-11-11
Daniel Gordon Kirby (Chief Commercial Officer)EXERCISE10,0002026-11-10
Daniel Gordon Kirby (Chief Commercial Officer)TAX-W3,935$32K2026-11-10

Full institutional holdings, insider history, and congressional trades for Iovance Biotherapeutics, Inc. Common Stock on SentiSense.